Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Price Target from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $10.00.

Several equities research analysts have commented on AMRX shares. Piper Sandler boosted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the sale, the director now owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 203,657 shares of company stock worth $1,667,887 over the last quarter. 26.56% of the stock is currently owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently modified their holdings of the company. Franklin Resources Inc. boosted its position in Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after purchasing an additional 4,178 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $37,000. Arizona State Retirement System boosted its holdings in shares of Amneal Pharmaceuticals by 13.6% in the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock worth $320,000 after buying an additional 4,851 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Amneal Pharmaceuticals by 13.6% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock valued at $366,000 after buying an additional 5,523 shares during the period. Finally, Segall Bryant & Hamill LLC increased its holdings in Amneal Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock valued at $4,070,000 after buying an additional 7,661 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $7.85 on Monday. The company has a 50 day simple moving average of $8.13 and a two-hundred day simple moving average of $8.24. Amneal Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -11.54 and a beta of 1.10.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.